D. Flannery, S. Gouma, Miren B Dhudasia, S. Mukhopadhyay, M. R. Pfeifer, E. C. Woodford, J. Gerber, C. P. Arevalo, M. Bolton, M. Weirick, E. Goodwin, E. M. Anderson, A. Greenplate, J. Kim, N. Han, A. Pattekar, J. Dougherty, O. Kuthuru, D. Mathew, A. Baxter, L. Vella, J. Weaver, A. Verma, R. Leite, J. Morris, D. Rader, M. Elovitz, E. Wherry, K. Puopolo, S. Hensley
medRxiv, 2020
Limited data are available for pregnant women affected by SARS-CoV-2. Serological tests are critically important to determine exposure and immunity to SARS-CoV-2 within both individuals and populations. We completed SARS-CoV-2 serological testing of 1,293 parturient women at two centers in Philadelphia from April 4 to June 3, 2020. We tested 834 pre-pandemic samples collected in 2019 and 15 samples from COVID-19 recovered donors to validate our assay, which has a ~1% false positive rate. We found 80/1,293 (6.2%) of parturient women possessed IgG and/or IgM SARS-CoV-2-specific antibodies. We found race/ethnicity differences in seroprevalence rates, with higher rates in Black/non-Hispanic and Hispanic/Latino women. Of the 72 seropositive women who also received nasopharyngeal polymerase chain reaction testing during pregnancy, 46 (64%) were positive. Continued serologic surveillance among pregnant women may inform perinatal clinical practices and can potentially be used to estimate seroprevalence within the community.
Cited by 9 publications.
Field of study: Medicine